Uzbekistan
UDK 61 Медицина. Охрана здоровья
The issues of the pathogenesis of hyperuricemia currently remain relevant due to the steady increase in the frequency of hyperuricemia and gout in polymorbid pathologies. Currently, a sufficient number of scientific papers have been accumulated on the association of hyperuricemia with cardiovascular diseases and their consequences (stroke and myocardial infarction), metabolic syndrome, arterial hypertension, insulin resistance, type 2 diabetes mellitus, chronic kidney disease, lipid metabolism disorders, atrial fibrillation, with the risk of mortality.
purine metabolism, hyperuricemia, gout, comorbid diseases
1. Eliseeva M.E., Eliseev M.S. Znachenie giperurikemii v razvitii zabolevaniy cheloveka i metody ee korrekcii Kardiologiya Terapiya № 2 (157), 2019 str.47-56
2. Park J.J., Roudier M.P., Soman D., Mokadam N.A., Simkin P.A. Prevalence of birefringent crystals in cardiac and prostatic tissues, an observational study. BMJ Open. 2014; 4(7): e005308. DOI: 10.1136/
3. Dalbeth N., House M.E., Aati O., Tan P., Franklin C., Horne A. et al. Urate crystal deposition in asymptomatic hyperuricaemia and symptomatic gout: a dual energy CT study. Ann. Rheum. Dis. 2015; 74(5): 908-11.DOI:https://doi.org/10.1136/annrheumdis-2014-206397
4. Nakagawa T., Mazzali M., Kang D-H. et al. Hyperuricemia causes glomerular hypertrophy in the rat. Am J Nephrol 2003;23:2-7.
5. Lehto S., Niskanen L., Ronnemaa T. et al. Serum uric acid is a strong predictor of stroke in patients with non-insulin-independent diabetes mellitus. Stroke. 1998; 29: 635-9)
6. Denisov IS, Eliseev MS, Barskova VG. Ishody podagry. Obzor literatury. Chast' II. Komorbidnye zabolevaniya, risk razvitiya serdechno-sosudistyh katastrof i smerti pri podagre. Nauchno-prakticheskaya revmatologiya. 2013;51(6):703-10.
7. Choi HK, Ford ES, Li C, Curhan G. Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2007;57(1):109-15. doi:https://doi.org/10.1002/art.22466
8. Eliseev M.S., Novikova A.M. Komorbidnost' pri podagre i giperurikemii: rasprostranennost', prichiny, perspektivy uratsnizhayuschey terapii. Terapevticheskiy arhiv. 2019; 91 (5): 120-128. DOI:https://doi.org/10.26442/00403660.2019.05.000232
9. Uzbekova N.R. Neyrogumoral'nye mehanizmy patogeneza metabolicheskogo sindroma. Disser.dokt.med.nauk, Tashkent, 2017
10. Mayko O.Yu., Ivanova K.V. Nekotorye Aspekty Racional'noy Terapii Arterial'noy Gipertonii U Bol'nyh Podagroy I Bessimptomnoy Giperurikemiey, Klinicheskaya Gerontologiya, 5-6, 2015 Str60-67,
11. Johnson R.J., Rodriguez-Iturbe B., Kang D.H. et al. A unifying pathway for essential hypertension. Am J Hypertens 2005;18:431-40.
12. Fang J., Alderman M. Serum uric acid and cardiovascular mortality: The NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA. 2000; 238:2404-10
13. Barskova V.G. i dr. Diagnostika podagry (lekciya) // Nauchno-prakticheskaya revmatologiya. 2012. № 4. S. 62-66
14. Xue Li. Phenome-wide association study (PheWAS) on the genetic determinants of serum urate leveland disease outcomes in UK Biobank. Doctor of Philosophy - The University of Edinburgh - 2018.
15. Biscaglia S., Ceconi C., Malagù M., Pavasini R., Ferrari R. Uric acid and coronary artery disease: An elusive link deserving further attention. Int. J. Cardiol. 2016; 213: 28-32.
16. Kobalava Zh.D., Troickaya E.A. Bessimptomnaya giperurikemiya i risk razvitiya serdechno-sosudistyh i pochechnyh zabolevaniy. Kardiologiya. 2020;60(10):113-121
17. Bardin T, Richette P. Definition of hyperuricemia and gouty conditions. Current opinion in rheumatology. 2014;26(2):186-91
18. Desideri G, Castaldo G, Lombardi A, Mussap M, Testa A, Pontremoli R, et al. Is it time to revise the normal range of serum uric acid levels? European review for medical and pharmacological sciences. 2014;18(9):1295-306.
19. Richette P, Doherty M, Pascual E, et al. Ann Rheum Dissertation 2020;79:33.
20. «Obnovlennye v 2018 g. rekomendacii Evropeyskoy protivorevmaticheskoy ligi po diagnostike podagry, osnovannye na fakticheskih dannyh» (2020g.)
21. Rekomendacii Francuzskogo obschestva revmatologov 2020 g.
22. V.V. Curko, I.V. Egorov, M.V. Eliseeva//Podagra u pozhilyh pacientov, svyaz' s komorbidnost'yu / Praktikuyuschiy vrach segodnya. 2013. №1. S. 2-9.
23. Choi HK, Ford ES, Li C, Curhan G. Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2007;57(1):109-15. doi:https://doi.org/10.1002/art.22466
24. Eliseev M.S., Barskova V.G., Denisov I.S. Dinamika klinicheskih proyavleniy podagry u muzhchin (dannye 7-letnego retrospektivnogo nablyudeniya). Terapevticheskiy arhiv. - 2015.T. 87. - № 5. - S. 10-5.
25. Bekmatova Sh.K. Struktura Metabolicheskogo Sindroma I Ego Klinicheskoe Znachenie V Razlichnye Periody Zhizni, disser. PhD, Urgench,2021str.5
26. Cicero A.F., Rosticci M., Fogacci F., Grandi E., D'Addato S., Borghi C.; Brisighella Heart Study Group. High serum uric acid is associated to poorly controlled blood pressure and higher arterial stiffness in hypertensive subjects. Eur. J. Intern. Med. 2017; 37: 38-42. DOIhttps://doi.org/10.1016/j.ejim.2016.07.026.
27. Ramirez A.J., Christen A.I., Sanchez R.A. Serum Uric Acid Elevation is Associated to Arterial Stiffness in Hypertensive Patients with Metabolic Disturbances. Curr. Hypertens. Rev. 2018; 14(2): 154-60. DOIhttps://doi.org/10.2174/1573402114666180413143312
28. Ruda M.M., Karpov Yu.A.. Giperurikemiya i serdechno-sosudistyy risk: sovremennyy vzglyad na problemu. AtmosferA. Novosti kardiologii 1*2020str3-15
29. Toirov H.K., Kardiovaskulyarnye narusheniya pri podagre. Disst. kmn.2013.Dushanbe
30. Topolyanskaya S.V., Vakulenko O.N., Semashkova A.E., Kupina L.M., Strizhova N.V. Giperurikemiya i serdechno-sosudistye zabolevaniya v starcheskom vozraste. Klin. Med. 2017; 95 (5): 457-464.DOI http://dx.doi.org/10.18821/0023-2149-2017-95-5-457-464
31. Campo C., Ruilope L.M., Segura J. et al. Hyperuricemia, low urine urate excretion and target organ damage in arterial hypertension. Blood press. 2003; 12: 277-283.
32. Puddu P., Puddu G.M., Cravero E., Vizioli L., Muscari A. The relationships among hyperuricemia, endothelial dysfunction, and cardiovascular diseases: Molecular mechanisms and clinical implications.J. Cardiol. 2012; 59: 235-42.
33. Puig J.G., Ruilope L.M. Uric acid as a cardiovascular risk factor in arterial hypertension. J Hypertens 1999;17:869-72
34. Qin T., Zhou X., Wang J., Wu X., Li Y., Wang L. et al. Hyperuricemia andthe Prognosis of Hypertensive Patients: A Systematic Reviewand MetaAnalysis. J. Clin. Hypertens. (Greenwich). 2016; 18(12): 1268-78. DOIhttps://doi.org/10.1111/jch.12855
35. Kuwabara M, Niwa K, Nishihara S, Nishi Y, Takahashi O, Kario K, Yamamoto K, Yamashita T, Hisatome I. Hyperuricemia is an independent competing risk factor for atrial fibrillation. International Journal of Cardiology 2017 Mar;231:137-42
36. Lin K.C., Lin H.Y., Chou P. The interaction between uric acid level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study. J. Rheumatol. 2000; 27(6): 1501-5.;
37. Lehto S., Niskanen L., Ronnemaa T. et al. Serum uric acid is a strong predictor of stroke in patients with non-insulin-independent diabetes mellitus. Stroke. 1998; 29: 635-9)
38. Nedogoda S.V., Salasyuk A.S., Barykina I.N., Ledyaeva A.A., Coma V.V., Chumachek E.V., Hripaeva V.Yu. Vozmozhnosti Korrekcii Giperurikemii Pri Metabolicheskom Sindrome.Medicinskiy sovet №2,2014 str 18-24
39. Abreu E, Fonseca MJ, Santos AC. Association between hyperuricemia and insulin resistance. Acta Med Port, 2011, 2: 565-574.
40. Il'ina A.E., Barskova V.G., Nasonov E.L. Bessimptomnaya giperurikemiya - pol'za ili vred? RMZh. - 2008. - № 24. - S. 1619. / Il'ina AE, Barskova VG, Nasonov EL. Bessimptomnaya giperurikemiya - pol'za ili vred? RMZH. 2008; 24: 1619. [in Russian].
41. Orlova E.V.Giperurikemiya v terapevticheskoy praktike - lechit' ili nablyudat'/ Trudnyy pacient №10, TOM 16, 2018 str.17 DOI:https://doi.org/10.24411/2074-1995-2018-10015)
42. Fang J., Alderman M. Serum uric acid and cardiovascular mortality: The NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA. 2000; 238:2404-10
43. Barskova VG, Il'inyh EV, Eliseev MS i dr. Kardiovaskulyarnyy risk u bol'nyh podagroy. Ozhirenie i metabolizm. 2006;(3):40-44.
44. Viazzi F., Parodi D., Leoncini G. et al. Serum uric acid and target organ damage in primary hypertension. Hypertension. 2005; 45: 991- 996
